Biomarker & Intervention Discovery

Other Musculoskeletal Disorders

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

IL6 173PTGS2 299SCN9A 271TNF 277TRPV1 160
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 inhibits Mechanistic
MRA 003 US inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN inhibits Mechanistic 102.0 nM (IC50)
INDOMETHACIN SODIUM inhibits Mechanistic
DARBUFELONE ? unclear Mechanistic
MEFENAMIC ACID inhibits Mechanistic
MECLOFENAMATE SODIUM inhibits Mechanistic
DICLOFENAC SODIUM inhibits Mechanistic
CAPECITABINE ? unclear Mechanistic
PIRPROFEN inhibits Mechanistic
ESFLURBIPROFEN inhibits Mechanistic
SULFASALAZINE inhibits Mechanistic
BROMFENAC ? unclear Mechanistic
IBUPROFEN, SODIUM SALT inhibits Mechanistic
ALOXIPRIN inhibits Mechanistic
TENOXICAM ? unclear Mechanistic
FLURBIPROFEN inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
DEXKETOPROFEN inhibits Mechanistic
ETORICOXIB inhibits Mechanistic
LUMIRACOXIB inhibits Mechanistic
SUPROFEN inhibits Mechanistic
NS-398 ? unclear Mechanistic
NABUMETONE inhibits Mechanistic
URSOLIC ACID ? unclear Mechanistic
IBUPROFEN LYSINE inhibits Mechanistic
ACECLOFENAC inhibits Mechanistic
IBUFENAC inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
DIFLUNISAL inhibits Mechanistic
BALSALAZIDE DISODIUM inhibits Mechanistic
VACCINE ? unclear Mechanistic
KETOROLAC TROMETHAMINE inhibits Mechanistic
BENZYDAMINE HYDROCHLORIDE inhibits Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
NAPROXCINOD inhibits Mechanistic
IGURATIMOD inhibits Mechanistic
ETODOLAC inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM inhibits Mechanistic
ROFECOXIB inhibits Mechanistic 530.0 nM (IC50)

Showing top 40 of 299 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MERETHOXYLLINE PROCAINE inhibits Mechanistic
ETIDOCAINE HYDROCHLORIDE inhibits Mechanistic
FOSPHENYTOIN inhibits Mechanistic
VERATRIDINE activates Mechanistic
ORPHENADRINE CITRATE inhibits Mechanistic
PHENACEMIDE inhibits Mechanistic
LACOSAMIDE inhibits Mechanistic
VIXOTRIGINE inhibits Mechanistic
DSP-2230 inhibits Mechanistic
SAXITOXIN inhibits Mechanistic
ESLICARBAZEPINE ACETATE inhibits Mechanistic
SAFINAMIDE ? unclear Mechanistic
LIDOCAINE inhibits Mechanistic
RILUZOLE inhibits Mechanistic
ROPIVACAINE HYDROCHLORIDE inhibits Mechanistic
FUNAPIDE inhibits Mechanistic
DYCLONINE HYDROCHLORIDE inhibits Mechanistic
EVENAMIDE inhibits Mechanistic
PROPOFOL ? unclear Mechanistic
AM-6120 inhibits Mechanistic
RG7893 inhibits Mechanistic
RG6029 inhibits Mechanistic
QUINIDINE SULFATE inhibits Mechanistic
ZONISAMIDE inhibits Mechanistic
NERISPIRDINE inhibits Mechanistic
RALFINAMIDE inhibits Mechanistic
DS-1971A inhibits Mechanistic
HEXYLCAINE HYDROCHLORIDE inhibits Mechanistic
MEPIVACAINE HYDROCHLORIDE inhibits Mechanistic
PROCAINAMIDE HYDROCHLORIDE inhibits Mechanistic
PROPAFENONE HYDROCHLORIDE inhibits Mechanistic
LIDOCAINE HYDROCHLORIDE inhibits Mechanistic
QUINIDINE GLUCONATE inhibits Mechanistic
PRILOCAINE inhibits Mechanistic
ETHOTOIN inhibits Mechanistic
PF-05089771 inhibits Mechanistic
DICHLOROBENZYL ALCOHOL inhibits Mechanistic
RANOLAZINE ? unclear Mechanistic
PRILOCAINE HYDROCHLORIDE inhibits Mechanistic
ORPHENADRINE HYDROCHLORIDE inhibits Mechanistic

Showing top 40 of 271 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
NERELIMOMAB inhibits Mechanistic
CROMOLYN SODIUM ? unclear Mechanistic
PLACULUMAB inhibits Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
GENTAMICIN ? unclear Mechanistic
GOLIMUMAB inhibits Mechanistic
BUPIVACAINE ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic 85000.0 nM (IC50)
BENZO[E]PYRENE ? unclear Mechanistic
THALIDOMIDE ? unclear Mechanistic
PYRAZINAMIDE ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
LENERCEPT inhibits Mechanistic
ADALIMUMAB inhibits Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
LENABASUM ? unclear Mechanistic
MAGNESIUM SULFATE ANHYDROUS ? unclear Mechanistic
PICIBANIL ? unclear Mechanistic
FLUOCINOLONE ACETONIDE ? unclear Mechanistic
MILTEFOSINE ? unclear Mechanistic
HOMIDIUM BROMIDE ? unclear Mechanistic
OZORALIZUMAB inhibits Mechanistic
PEGSUNERCEPT inhibits Mechanistic
CERTOLIZUMAB PEGOL inhibits Mechanistic
THERAPEUTIC HORMONE ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
FOLIC ACID ? unclear Mechanistic
ABBV-257 ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
COVA322 ? unclear Mechanistic
HYDROXYCHLOROQUINE ? unclear Mechanistic
CERTOLIZUMAB ? unclear Mechanistic
AN0128 ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SORAFENIB ? unclear Mechanistic

Showing top 40 of 277 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
STREPTOZOCIN ? unclear Mechanistic
BENZYL ISOTHIOCYANATE ? unclear Mechanistic
ACETAMINOPHEN activates Mechanistic
POLYGODIAL ? unclear Mechanistic
PROPOFOL ? unclear Mechanistic
SAF312 inhibits Mechanistic
GRC-15300 ? unclear Mechanistic
AZD1386 inhibits Mechanistic
TIVANISIRAN inhibits Mechanistic
MAVATREP inhibits Mechanistic
MR-1817 inhibits Mechanistic
FERRUGINENE B ? unclear Mechanistic
CAPSAICIN activates Mechanistic 19.95 nM (EC50)
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic
VOACANGINE ? unclear Mechanistic
RESINIFERATOXIN activates Mechanistic 23.1 nM (Ki)
DWP05195 inhibits Mechanistic
XEN-D0501 inhibits Mechanistic
PAC-14028 inhibits Mechanistic
SB-705498 inhibits Mechanistic
MASOPROCOL ? unclear Mechanistic
ALLYL ISOTHIOCYANATE ? unclear Mechanistic
NGD-8243 inhibits Mechanistic
GRC-6211 inhibits Mechanistic
RESERPINE ? unclear Mechanistic
NABIXIMOLS ? unclear Mechanistic
A425619 ? unclear Mechanistic
PHE377 inhibits Mechanistic
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic
WORTMANNIN ? unclear Mechanistic
JTS-653 inhibits Mechanistic
LEVODOPA ? unclear Mechanistic
AMG517 inhibits Mechanistic
CAPSAZEPINE ? unclear Mechanistic 120.0 nM (Ki)
ZUCAPSAICIN activates Mechanistic
INDOMETHACIN ? unclear Mechanistic
CHEMBL:CHEMBL191534 ? unclear Mechanistic
ABT-102 inhibits Mechanistic
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic

Showing top 40 of 160 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT07157852 Phase: NA Started: 2025-09-05

Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is l...

NCT02281747 Phase: N/A Started: 2014-10-24

Background: \- Orthopedic procedures are common in the United States. These include joint replacement and spine surgeries. Researchers want to study data about these procedures over time. They want to see if treatment has gotten better. They also want to find ways to change the care that people get...

NCT03093909 Phase: PHASE1 Started: 2017-11-22

Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have sp...

NCT03050268 Phase: N/A Started: 2017-04-06

NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor o...

NCT07639944 Phase: NA Started: 2026-05-04

Temporomandibular disorders (TMD) encompass a group of conditions involving the masticatory muscles, temporomandibular joint (TMJ), and associated structures. TMD is the most common cause of non-odontogenic orofacial pain and is the second most commonly occurring musculoskeletal condition. Up to 70%...

NCT03270982 Phase: N/A Started: 2016-04

Clinical Data evaluation to document the performance and clinical outcomes of the Comprehensive Segmental Revision System.

NCT03449108 Phase: PHASE2 Started: 2018-04-27

This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to tre...

NCT07284641 Phase: PHASE2 Started: 2026-05-04

This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory D...

NCT01852851 Phase: NA Started: 2013-06

The investigators plan to conduct a randomized controlled trial to evaluate the effectiveness and the cost effectiveness of an on-line eLearning program (entitled Employment and Arthritis: Making it Work) designed to help people with inflammatory arthritis stay employed. The program also includes as...

NCT07167784 Phase: N/A Started: 2025-11-24

Chronic inflammatory rheumatic diseases (IRDs), such as rheumatoid arthritis and spondyloarthritis, can cause pain, fatigue, and mobility issues, significantly impacting patients' quality of life. Physical activity is an important part of managing these conditions, as it helps reduce pain, maintain ...

NCT02075775 Phase: N/A Started: 2012-08

This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to comple...

NCT04670679 Phase: PHASE1 Started: 2020-12-15

* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ...

NCT07475663 Phase: PHASE3 Started: 2025-11-04

The goal of this clinical trial is to learn if a gel containing Piroxicam plus Counterirritant (warming/cooling ingredients) is as effective and safe as two other common anti-inflammatory gels for treating acute muscle, bone, and joint pain in adults aged 18-60. The main questions it aims to answer ...

NCT04572295 Phase: PHASE1 Started: 2020-10-09

The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to determine the recommended dose (RD) of E7090 in combination with other antica...

NCT05067543 Phase: N/A Started: 2021-09-12

This study is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up study, which is designed to collect safety and performance data at baseline, surgery, immediate post-op and annually through 10 years post-operation. Data collected from this s...


Agents Found By Disease-Level Search

Searched directly from “Other Musculoskeletal Disorders” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 5-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.